We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amryt Pharma Plc | LSE:AMYT | London | Ordinary Share | GB00BKLTQ412 | ORD 6P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 143.00 | 151.00 | 170.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
27/4/2017 11:53 | "It's a great shame AMYT don't own the IP to Lojuxta, we are adding value to someone else.". BUT also adding value to AMYT, tightfist. Have a look at the information concerning the Lojuxta licensing deal in the relevant AMYT RNS's. "Yes I see that amyrt just has an excusive license for the European economic area.". Not just that area, geoffsmith. I'm happy to continue to hold, AMYT and to maybe add on the dips. Unlike runwaypaul I'm NOT a "pumper & dumper" share ramper & deramper trader! Jacksonpollack is always complaining about the "BoD sitting on their backsides doing SFA for their wages", but then they are NOT a charity doing their work for the benefit of small shareholders! They are out to make money for themselves and hopefully, in the process, we will also make money. One thing is for certain the only TWO Executive Directors haven't been "sitting on their backsides doing SFA for their wages"! | papillon | |
27/4/2017 11:01 | Hi Geoff Thanks for your reply. The problem with Lojuxta is it's cost. It is about 30k for 1 month's supply. If it does was the report says it can do, take up will improve and costs will come down. All the best. IB | icebreaker | |
27/4/2017 11:01 | My comment yesterday about News Flow was well timed!It's a great shame AMYT don't own the IP to Lojuxta, we are adding value to someone else. Maybe it is a complementary commitment within the licence deal?.I am very curious that this work/potential hasn't already been executed in the U.S.? Or is the European or Italian setting radically different?Whatever, this cannot do the sales/margin of Lojuxta in Europe, MENA, Turkey any harm! And presumably we are now assured to hit the revenue targets with corresponding milestone payments.Cheers, tightfist | tightfist | |
27/4/2017 10:54 | Hi Icebreaker, Yes I see that amyrt just has an excusive license for the European economic area. But say that big pharma want to own lojuxta, then surely they will want to buy that license back to take full control. If not either way this news surely indicates a potential very large uptake of the prescribing of Lojuxta. | geoffsmith | |
27/4/2017 10:53 | Buffy: I looked at the RNS again. It does say "Ten of the 15 patients..." | bigwavedave | |
27/4/2017 10:51 | Up 11% now which is more like it. I had double that in mind. | bigwavedave | |
27/4/2017 10:43 | Hi Geoff If the big pharma do want Lojuxta they will surely go after Aegerion (subsidiary of Novelion) whose product it is? Good luck. | icebreaker | |
27/4/2017 10:27 | curnic1, If Lojuxta does really do what this rns says then we don't need a flood of news anyway, I don't think the market has woken up yet to what this means. The big pharma companies will want this, am I dreaming or is this news real? | geoffsmith | |
27/4/2017 10:20 | Massive News, Great News take your pick and this is just the start of a flood of Brilliant News in the near future. | curnic1 | |
27/4/2017 10:11 | Have I read this rns right I wonder, I have now read it all three times and cant really believe how good this appears, I know three men who have been on statins and found the side effects to be intolerable, so much so that they have stopped taking them,one of whom is now still suffering very unpleasant side effects some two years later. It reads to me that Lojuxta could and will replace statins for a hugh amount of people with bad cholesterol. Is this massive good news or what? | geoffsmith | |
27/4/2017 10:06 | runwaypaul26 Apr '17 - 10:23 - 1074 of 1080 0 0 paps Hot Stock Rocket says STRONG HOLD. you know what you need to do.gl >>>>> In the light of today's RNS, runwaypaul, I should have bought yesterday!!!!!!!!!!! How many times do I have to tell you I do NOT base investment decisions on Hot Stock Rockets (which I DON'T subscribe to)/ShareProphets tips. You really are rather slow on the uptake runwaypaul! LOL. PS. The AMYT chart signals were saying sell AMYT yesterday, but a good(ish) RNS can blow a chart signal to smithereens! | papillon | |
27/4/2017 09:08 | Well spotted buffy. Maybe the answer is in the full study. I only read the RNS with one eye open this morning but did expect a much higher move on this news which I think is excellent. Will read it properly later. | bigwavedave | |
27/4/2017 06:53 | There were only 10 receiving aphoresis. It is those 10 he is referring too I think. | icebreaker | |
27/4/2017 06:18 | 15 patients 80% were able to stop the treatment The remaining 2 had their dose reduced Either the number of patients was 10 or the number of patients that didn't stop treatment was 3. What's happened to Mark Sumeray? Buffy | buffythebuffoon | |
27/4/2017 06:13 | Buy the dips Sir! | ny boy | |
27/4/2017 06:12 | Unexpected update today. Very positive I think. | hutch_pod | |
26/4/2017 09:23 | paps Hot Stock Rocket says STRONG HOLD. you know what you need to do.gl pmsl | runwaypaul | |
26/4/2017 08:20 | Icebreaker, papillon,Thanks for your overviews, very useful, as is the Mark Sumerary interview. Definitely a game of patience on trials of Episalvan for EB, so for newcomer I suppose it's about picking your entry point when boredom sets in, UNLESS there is other news flow in the wings - Amryt does appear to be pretty active on the news front.The EIB funding line looks interesting too.Cheers, tightfist | tightfist | |
26/4/2017 08:00 | £10 Million per annum. Little more than a bonus! Good luck. | icebreaker | |
26/4/2017 07:50 | Lojuuxta appeared to have been given away because others tried & failed - anything positive from that additional venture is a Bonus, imo. | pottermagic2310 | |
25/4/2017 20:50 | Hi Pottermagic2310 I am not sure that's right. The Lojuxta deal was not merely put in place to support the funding requirements of various high risk studies. It was about the diversification of the business. Moreover, the Lojuxta deal required that Amryt set up distribution infrastructures. It would not make sense that these channels to market were utilised only by one drug. I fully expect more licence deals in a similar sector. Look at Harry Stratford's bio to see how he has worked in the past. He is not in this to make a few quid on one (or two) high risk drugs (above all else, he doesn't need too). He builds businesses with products, revenues, expertise and market dominance! As you may know, Lojuxta raised $100m net last year in the US. We are licenced in an area with 3x the population. I am really struggling to understand what investors are failing to see here? We are even covered financially for the next 18 months unlike almost any other AIM company! IB | icebreaker | |
25/4/2017 19:21 | The share price is going to fall simply because nothing much is going to change between now and 12-18 months time... according to the Business Plan and recent RNS' issued by the Business. We just have to sit tight again and watch what unfolds, hopeful witnessing a +ve outcome re the Trials. | pottermagic2310 | |
25/4/2017 15:46 | MACD definitely indicated a SELL 3 days ago. RSI (14) is falling. AMYT share price looks likely to fall further still before MACD & RSI indicate it might be worth buying again. Of course we could get an RNS that blows the chart indicators away, but that is looking very unlikely. I wouldn't recommend, tightfist, buying AMYT now. There will be a better time to purchase; hopefully you wont have to wait too long! | papillon |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions